Azacytidine, our fantastic hypomethylating agent, used for treatment of MDS and AML, was discovered in 1964, and then fell into oblivion. Almost 40 years later it was FDA approved as the first effective MDS treatment.
A 🧵about an unusual revival:
🧵 1/6 Now online @BloodPortfolio: Time to revise/re-evaluate #Myeloma Diagnostic Criteria? @ManniMD1 and I make an argument that sFLC ratio≥100 should not be used as a standalone criterion due to the risk of systematic overdiagnosis and overtreatment!
(Figure below shows that this is a heterogeneous group with a vast majority having a low risk of progression to CRAB MM)
https://t.co/JshuBxmNKB
The patient persisted asymptomatic. Further studies were performed HTLV 1 and 2 negative. Euro-flow: Mature T lymphocytes 83% with asynchrony in maturation, expression of: CD99+ CD2+, CD5+, CD7+, CD45RA+ CD3c+ CD3m+, CD44+, CD8+, CD10- CD56-, CD117-, CD4-, CD33- (4/5)
Peripheral blood smear shown mature and small lymphocytes without blebs or atypical forms. CT scan was normal, a Bone marrow biopsy was performed with the same morphology of small and mature lymphocytes CD3+, CD5+, CD8+ CD7+++ with conclusion of a PTCL-NOS CD8+. (3/5)
@DrChavezDiaz Cada quien responde acorde a sus experiencias. En mi caso, Doctoralia me ha ayudado mucho. A la fecha tiene distintos formatos y formas de pago; existen muchos factores tales como lugar de consultorio (competencia), días de consulta. A mi, si me ha ayudado mucho 👍🏼
#Weekend_review 🧵 #IMresident#hemoncfellows
1/10 JAK2 unmutated or non-PV erythrocytosis or idiopathic erythrocytosis
Not every polycythemia/erythrocytosis is polycythemia vera (PV)!
JAK2 unmutated or non-PV erythrocytosis: hereditary and acquired.
Up to 70% of cases, erythrocytosis remain uncharacterized “idiopathic”
New article alert:
Anticoagulant prophylaxis in pregnant women with a history of venous thromboembolism: A systematic review and meta-analysis
https://t.co/ekBOnwf5Tn
@ELShematology @ThrombUpdate@LucyNORTCD